55676-21-6

Basic information

• Product Name: 3-ACETYL-2-CHLOROPYRIDINE
• Synonyms: 1-(2-chloro-3-pyridinyl)-1-ethanone;2-chloro-3-acetylpyridine;1-(2-chloro-3-pyridinyl)ethanone;1-(2-chloro-3-pyridinyl)ethanone(SALTDATA: FREE);1-(2-chloropyridin-3-yl)ethan-1-one;1-(2-Chloropyridin-3-yl)ethan-1-one, 2-Chloro-3-ethanoylpyridine;3-Acetyl-2-chloropyridine 95%;Ethanone, 1-(2-chloro-3-pyridinyl)-
• CAS NO: 55676-21-6
• Molecular Formula: C₇H₆ClNO
• Molecular Weight: 155.58
• EINECS: -0
• Product Categories: pharmacetical;Pyridine series;alkyl chloride
• Mol File: 55676-21-6.mol

Chemical Properties

• Boiling Point: 114°C/15mmHg(lit.)
• Flash Point: >110℃
• Appearance: /
• Density: 1.233 g/cm³
• Vapor Pressure: 0.06mmHg at 25°C
• Refractive Index: 1.5440-1.5480
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -1.65±0.10(Predicted)
• CAS DataBase Reference: 3-ACETYL-2-CHLOROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ACETYL-2-CHLOROPYRIDINE(55676-21-6)
• EPA Substance Registry System: 3-ACETYL-2-CHLOROPYRIDINE(55676-21-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 55676-21-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Acetyl-2-chloropyridine is used as a reagent for the synthesis of Volitinib, a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor. This makes it a crucial component in the development of anti-cancer agents, specifically targeting c-Met pathways that are implicated in the growth and progression of various types of cancer.

InChI:InChI=1/C7H6ClNO/c1-5(10)6-3-2-4-9-7(6)8/h2-4H,1H3

Upstream product

• 14188-94-4 3-acetylpyridine N-oxide 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 917-64-6 methyl magnesium iodide 
• 131674-39-0 2-chloro-3-(1-hydroxyethyl)pyridine 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 75-16-1 methylmagnesium bromide 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 350-03-8 methyl-3-pyridylketone 
• 109-09-1 2-chloropyridine 
• 2942-59-8 2-chloronicotinic acid 
• 79-37-8 oxalyl dichloride 
• 594-27-4 tetramethylstannane 
• 144-55-8 sodium hydrogencarbonate 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 131674-40-3 1-(2-methoxypyridin-3-yl)ethanone 
• 62838-65-7 1-(2-hydroxypyridin-3-yl)ethanone 
• 65326-33-2 1-(2-amino-3-pyridinyl)-1-ethanone 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 
• 116834-97-0 1,3-dimethylpyrazolo<3,4-b>pyridine 
• 232602-14-1 1-(2-benzyl-pyridin-3-yl)-ethanone 
• 166196-84-5 1-(2-chloropyridin-3-yl)-3-dimethylaminopropenone 
• 942274-97-7 methyl 2-(3-acetylpyridin-2-yl)benzoate 
• 870221-17-3 4-(2-chloropyridin-3-yl)pyrimidine 
• 870221-22-0 4-(2-chloropyridin-3-yl)-N-methylpyrimidin-2-amine 
• 926277-91-0 4-methyl-3-(3-(pyrimidin-4-yl)pyridin-2-yloxy)benzoic acid 
• 870221-16-2 4-methyl-3-(3-(pyrimidin-4-yl)pyridin-2-ylamino)benzoic acid 
• 926277-89-6 4-methyl-3-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)benzoic acid 

Relevant articles and documents

Difluorocarbene-triggered cyclization: Synthesis of (hetero)arene-fused 2,2-difluoro-2,3-dihydrothiophenes

An efficient method for the synthesis of (hetero)arene-fused 2,2-difluoro-2,3-dihydrothiophene derivatives using readily available sodium chlorodifluoroacetate (ClCF2CO2Na) has been developed. This transformation is achieved through a combination of a thi

INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF

Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids

Activation of the CB2 receptor is an attractive therapeutic strategy for the treatment of a wide range of inflammatory diseases. However, receptor subtype selectivity is necessary in order to circumvent the psychoactive effects associated with activation of the CB1 receptor. We aimed to use potent, non-selective synthetic cannabinoids designer drugs to develop selective CB2 receptor agonists. Simple structural modifications such as moving the amide substituent of 3-amidoalkylindole synthetic cannabinoids to the 2-position and bioisosteric replacement of the indole core to the 7-azaindole scaffold are shown to be effective and general strategies to impart receptor subtype selectivity. 2-Amidoalkylindole 16 (EC50 CB1 > 10 μM, EC50 CB2 = 189 nM) and 3-amidoalkyl-7-azaindole 21 (EC50 CB1 > 10 μM, EC50 = 49 nM) were found to be potent and selective agonists with favourable physicochemical properties. Docking studies were used to elucidate the molecular basis for the observed receptor subtype selectivity for these compounds.

High-activity iminophenylacetate compound, preparation method and applications thereof

The present invention belongs to the field of pesticides, and particularly relates to a high-activity iminophenylacetate compound, a preparation method and applications thereof. According to the present invention, the research of novel methoxy acrylate compounds is performed, a pyridine aryl ether structure is introduced into the structure of the novel methoxy acrylate compound, the research of the new compound structures is expanded, and the high-activity iminophenylacetate compound is found; and the compound has the bioactivity equal to azoxystrobin and trifloxystrobin, provides good effects on most pathogenic bacteria, especially provides significant prevention and treatment effects on Sclerotinia sclerotiorum bacterial, and is effective at a low doses.

A Novel Synthesis of 1-Alkyl-2-phenyl-1,8-naphthyridin-4-one

Provided is a novel method for manufacturing 1-alkyl-2-phenyl-1,8-naphthyridin-4-one from 2-chloronicotinic acid. According to the present invention, 1-alkyl-2-phenyl-1,8-naphthyridin-4-one can be synthesized through simple reaction conditions and simple

3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

THIAZOLE DERIVATIVES FOR THE TREATMENT OF ANIMAL TRYPANOSOMIASIS

The present invention relates to a novel class of compounds of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein, to their use in human and veterinary medicine, and in the treatment of animal trypanosomiasis in particular, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.